北京时间2025年01月31日03时48分,凯信远达(CASI.us)股票出现波动,股价快速上涨6.34%。截至发稿,该股报2.52美元/股,成交量8807股,换手率0.06%,振幅5.92%。
最近的财报数据显示,该股实现营业收入7.79百万美元,净利润-8.40百万美元,每股收益-0.55美元,毛利4.05百万美元,市盈率-1.09倍。
机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。
凯信远达股票所在的生物技术行业中,整体涨幅为0.18%。其相关个股中,Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Nutriband Inc C/Wts (To Pur Com)涨幅较大,Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃,换手率分别为1801.69%、322.79%、251.81%,振幅较大的相关个股有Dominari Holdings Inc.、Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 (To Pur Com),振幅分别为70.55%、65.98%、64.10%。
凯信远达公司简介:CASI Pharmaceuticals Inc是一家生物制药公司,致力于将创新疗法和药物产品商业化。 该产品包括针对患有白血病和淋巴瘤的患者的注射剂。 EVOMELA注射液用于多发性骨髓瘤患者自体干细胞移植前作为条件治疗。 该公司的产品包括CID-103,CNCT19,EVOMELA,MARQIBO,ZEVALIN,ENMD-2076等。 大部分收入来自EVOMELA的产品销售。 该公司主要在美国,加拿大,中国和世界其他地区运营。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.